No Data
MiNK Therapeutics INKT Human Tissue Data; Adial Pharmaceuticals ADIL Reverse Split
MiNK Therapeutics Presents New Data of Allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
Express News | Mink Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-Inkt Cell Therapy (Agent-797) to Evaluate Prevention of Graft-Versus-Host Disease
Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
PoseidonsKiss : Not with the 150 mil offering.